Adaptive Biotechnologies Corporation (ADPT) Cash Flow Statement
Adaptive Biotechnologies Corporation (ADPT) generated -$21.0M of operating cash flow over the twelve months to 2026-06-30, spent $3.0M on capital expenditure and had free cash flow of -$24.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ADPTAdaptive Biotechnologies CorporationFollow ADPT — free
—
Price chart with a free account
- Market cap
- 4.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 10 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 0.21 | -0.15 | -0.19 | -0.18 | -0.16 | -0.10 | -0.05 | -0.02 | |
| Capital expenditure | 0.01 | 0.02 | 0.06 | 0.02 | 0.01 | 0.00 | 0.00 | -0.00 | |
| Free cash flow | 0.19 | -0.17 | -0.25 | -0.20 | -0.17 | -0.10 | -0.05 | -0.02 | |
| Stock-based compensation | 0.01 | 0.02 | 0.04 | 0.06 | 0.06 | 0.05 | 0.05 | — |
USD billions · SEC XBRL
Adaptive Biotechnologies Corporation — questions
- What is Adaptive Biotechnologies Corporation's operating cash flow?
- -$21.0M over the twelve months to 2026-06-30.
- How much does Adaptive Biotechnologies Corporation spend on capital expenditure?
- $3.0M over the twelve months to 2026-06-30.
- What is Adaptive Biotechnologies Corporation's free cash flow?
- -$24.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Adaptive Biotechnologies Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.